Annualized hospitalization rate with natalizumab vs fingolimod in second-line treatment for RRMS in the public healthcare system in Brazil: A claim database approach

PURPOSE: In the Brazilian public healthcare system, natalizumab is recommended as fourth-line treatment for relapsing-remitting multiple sclerosis (RRMS). Although natalizumab has already demonstrated higher effectiveness compared with fingolimod in some studies, this real-world study was conducted...

Descripción completa

Detalles Bibliográficos
Autores principales: Julian, Guilherme Silva, Rosim, Ricardo Papaléo, Carneseca, Estela Cristina, Rigolon, Jéssica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051079/
https://www.ncbi.nlm.nih.gov/pubmed/32119696
http://dx.doi.org/10.1371/journal.pone.0229768

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7051079/
https://www.ncbi.nlm.nih.gov/pubmed/32119696
http://dx.doi.org/10.1371/journal.pone.0229768

Ejemplares similares